Tuesday, May 30, 2023


Biotechnology News Magazine

DTCFF – RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to Accum(tm). The potency of this modified product will now be compared to “naked” mRNA administered as vaccines in immunocompetent mice.

The field of mRNA vaccination holds great promises over the use of other vaccination modalities. mRNA delivered to target cells makes them prone to harsh intracellular conditions such as the exhaustive acidity and enzymatic reactions found within endosomal lumens. As such, captured mRNA molecules may be destroyed before even reaching the cytoplasm where they are normally translated into proteins or long polypeptide chains. When tested in mice, administration of a “naked” mRNA molecule encoding for the ovalbumin protein triggered a weak to moderate antibody titers.

“Despite representing a promising technology, mRNA vaccines have not reached their full potential yet. By conjugating mRNA to AccumTM, we anticipate the immunogenicity of the vaccine to be enhanced resulting therefore in a powerful immune response,” says Dr. Rafei, the VP research and development of Defence Therapeutics.

Defence has now completed its AccumTM-mRNA vaccine engineering and synthesis. The final product is stable, and an SOP has been finalized to be able to apply the same method to any chosen mRNA molecule.

“The Defence AccumTM-mRNA vaccine program is on schedule. With this engineering steps completed, we are now initiating in vivo studies to compare the immunogenicity of the vaccine. The potency of the AccumTM-mRNA vaccine will be tested in animals on cancer solid T-cell lymphoma first, then subsequently on additional cancer solid tumors,” says Mr. Plouffe, CEO of Defence Therapeutics.

Defence plans to develop its own AccumTM-linked mRNA vaccines for different cancer indications. In parallel, the company is actively working on establishing partnerships with companies currently testing/developing mRNA vaccines for both immune-oncology and infectious disease indications.

The mRNA therapeutics market size is projected to surpass around USD 128.14 billion by 2030 and growing at a registered CAGR of 13.03% from 2022 to 2030 according to Precedence Research.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine